Skip to main content
OpenTrials
Completed

NCT Number: NCT04111263

Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude

The aim of this randomized, crossover clinical trial is to determine the efficacy of a gut microbiota-targeted nutritional intervention containing a blend of fermentable fibers and polyphenols (FP) for mitigating increases in GI permeability, and decrements in immune function and neuropsychologic performance following rapid ascent to simulated high altitude. Fifteen healthy young adults will participate in each of three study phases that include a 14-day supplementation period in which participants will consume 1 of 2 supplement bars: placebo (PL, will be consumed during 2 phases) and FP supplementation (will be consumed during one phase only). During the final 2-d of each phase, participants will live in a hypobaric chamber under sea level or high altitude conditions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

17 year–39 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

USARIEM

Natick, Massachusetts, 01760, United States

About this study

The collection of microbes inhabiting the human gastrointestinal (GI) tract, known as the gut microbiota, is increasingly recognized as a mediator of GI, immunologic, and neuropsychologic responses to various environmental and physiologic stressors. The hypobaric hypoxia characteristic of high altitude environments is a stressor that has recently been associated with increased GI permeability, and which has been shown to cause decrements in immune, neuropsychological and physical function. To what extent modulation of the human gut microbiota can mitigate these responses during high altitude exposure is undetermined. The aim of this randomized, crossover clinical trial is to determine the efficacy of a gut microbiota-targeted nutritional intervention containing a blend of fermentable fibers and polyphenols (FP) for mitigating increases in GI permeability, and decrements in immune function and neuropsychologic performance following rapid ascent to simulated high altitude. Fifteen healthy young adults will participate in each of three study phases in random order. Each phase will include a 14-day supplementation period in which participants will consume 1 of 2 supplement bars: placebo (PL, will be consumed during 2 phases) and FP supplementation (will be consumed during one phase only). During the final 2-d of each phase, participants will live in a hypobaric chamber. During one phase the chamber environment will mimic low-altitude conditions (SHAM). During two phases the chamber environment will mimic the barometric pressure at Pike's Peak CO (460 mmHg; HA).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged 18 - 39 years (active duty personnel who are 17 yr of age will also be allowed to participate)
  • In good health
  • Physically active
  • For active duty, passed most recent body composition assessment; for civilians, body mass index (BMI) ≤ 30.0 kg/m2.
  • Self-reports having a bowel movement at least as frequently as every-other-day
  • Self-reports normal vision (with or without glasses) and hearing

Exclusion criteria

  • Born at altitudes greater than 2,100 m (~7,000 feet)
  • Living in areas that are more than 1,200 m (~4,000 feet), or have traveled to areas that are more than 1,200 m for five days or more within the last 2 mo
  • Pregnant, expecting to become pregnant during study, or breastfeeding
  • Any of the following medical conditions:
  • Musculoskeletal injuries that compromise exercise capability
  • Metabolic or cardiovascular abnormalities (e.g., kidney disease, diabetes, cardiovascular disease, etc.)
  • Suspected or known strictures, fistulas, or physiological/mechanical GI obstruction
  • Evidence of apnea or other sleeping disorders
  • Evidence of prior high altitude pulmonary or cerebral edema diagnosis
  • Disease of the GI tract including, but not limited to diverticulitis, inflammatory bowel disease, peptic ulcer disease, Crohn's disease, ulcerative colitis
  • Anemia or Sickle Cell Anemia/Trait
  • Alcoholism or other substance abuse issues
  • History of gastric bezoar
  • Swallowing disorders; severe dysphagia to food or pills
  • Implanted or portable electro-mechanical medical devices
  • Allergy to skin adhesive
  • Past GI surgery
  • Colonoscopy within 3 months of study participation
  • Taking prescription medications other than a contraceptive (unless approved by Medical Office and study PI)
  • Regular use of over-the-counter medications (including antacids, laxatives, stool softeners, and anti-diarrheals) unless approved by Medical Office and study PI
  • Any use of antibiotics, except topical antibiotics, within 3 months of study participation
  • Not willing to refrain from using non-steroidal anti-inflammatory medications (NSAIDs) or antihistamine during the study
  • Not willing to stop consumption of prebiotic- or probiotic-containing supplements (e.g.,VSL#3, PRO-15, etc.), or other dietary supplements at least 2 weeks before and throughout study participation
  • Not willing to stop consumption of probiotic-containing foods (e.g., yogurt, etc.) during study participation.
  • Not willing to refrain from smoking any nicotine product (includes e-cigarettes), vaping, and chewing tobacco during controlled-diet periods.
  • Not willing to abstain from caffeine and alcohol during controlled-diet periods.
  • Allergies, intolerances, unwillingness or inability to eat provided foods and beverages
  • Following vegetarian/vegan diet
  • Unable to regularly sleep for 7-10 hr/night
  • Any previous blood donation, within 8 weeks of the first blood draw of the study, of a volume that when combined with the amount of blood to be collected during the study would exceed 550 mL

Treatment and study plan

FP

Dietary Supplement

Fiber and polyphenol blend

Placebo

Dietary Supplement

Matched placebo

High altitude

Other

Simulated high altitude in altitude chamber using hypobaric hypoxia

Sea level

Other

Sea level environment in altitude chamber

Primary outcomes

  1. Difference in intestinal permeability

    Time frame: Study days 20, 40 and 60

    Intestinal permeability measured by the ratio of the urinary excretion of sucralose and erythrirol

Secondary outcomes

  1. Difference in lipopolysaccharide binding protein concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting serum lipopolysaccharide binding protein concentration

  2. Difference in zonulin concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting serum zonulin concentration

  3. Difference in glucagon-like peptide-2 concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting serum glucagon-like peptide-2 concentration

  4. Difference in intestinal fatty acid binding protein concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum intestinal fatty acid binding protein concentration

  5. Difference in claudin-3 concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum claudin-3 concentration

  6. Difference in S100B concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum S100B concentration

  7. Difference in systemic inflammation

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting serum interleukin (IL) IL-6, IL-8, IL-10, IL-17, IL-1β, IL-1ra, tumor necrosis factor-α, interferon-γ concentrations

  8. Difference in intestinal inflammation

    Time frame: Study days 6, 18, 21, 23, 27, 39, 42, 44, 48, 60, 63, 65

    Fecal calprotectin concentration

  9. Difference in glucose concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum glucose concentrations

  10. Difference in insulin concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum insulin concentrations

  11. Difference in lactate concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum lactate concentrations

  12. Difference in glycerol concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum glycerol concentrations

  13. Difference in cortisol concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise serum cortisol concentrations

  14. Difference in bone specific alkaline phosphatase concentrations

    Time frame: Study days 20, 41, 62

    Fasting serum bone specific alkaline phosphatase concentration

  15. Difference in carboxy-terminal collagen crosslinks concentrations

    Time frame: Study days 20, 41, 62

    Fasting serum carboxy-terminal collagen crosslinks concentration

  16. Difference in tartrate resistant acid phosphatase concentrations

    Time frame: Study days 20, 41, 62

    Fasting serum tartrate resistant acid phosphatase concentration

  17. Difference in procollagen type 1 N-terminal propeptide concentrations

    Time frame: Study days 20, 41, 62

    Fasting serum procollagen type 1 N-terminal propeptide concentration

  18. Difference in osteocalcin concentrations

    Time frame: Study days 20, 41, 62

    Fasting serum osteocalcin concentration

  19. Difference in secretory immunoglobulin A concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Secretory immunoglobulin A concentrations in tear fluid and saliva

  20. Difference in immune cell phenotypes

    Time frame: Study days 21, 42, 63

    Immune cell phenotype by flow cytometry

  21. Difference in T-cell simulated cytokine production

    Time frame: Study days 21, 42, 63

    T-cell simulated cytokine production by cell culture and flow cytometry

  22. Difference in natural killer-cell cytotoxicity

    Time frame: Study days 21, 42, 63

    Natural killer-cell cytotoxicity by cell culture and flow cytometry

  23. Difference in development of acute mountain sickness

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Environmental Symptoms Questionnaire-short form. Acute Mountain Sickness will be measured multiple times daily using the Lake Louise scoring system wherein higher scores indicate more severe symptoms. AMS severity cutoffs will use mild (0.7-1.53), moderate (1.53-2.63), severe >=2.63

  24. Difference in gastrointestinal symptoms; quality of life

    Time frame: Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9

    Gastrointestinal symptoms measure by modified version of the gastrointestinal quality of life index wherein lower scores indicate more severe symptoms.

  25. Difference in gastrointestinal symptoms; irritable bowel syndrome

    Time frame: Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9

    Gastrointestinal symptoms measure by modified version of the irritable bowel syndrome symptom severity scale score wherein higher scores indicate more severe symptoms. Scored on scale of 0-500; symptom severity scored as mild (75-174), moderate (175-300), severe (>300).

  26. Difference in appetite

    Time frame: Study weeks 0, 1, 2, 3, 4, 5, 6, 7, 8, 9

    Hunger, fullness, desire to eat, and prospective consumption measured by 100 mm visual analog scale. Scored from 0-100 with higher scores indicating greater sensation.

  27. Difference in changes in mood state

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by Profile of Mood States Questionnaire; a 65-item inventory of self-reported mood states which factor into six mood sub-scales (tension/anxiety (0-36), depression/dejection (0-60), anger/hostility (0-48), vigor/activity (0-32), fatigue/inertia (0-28), confusion/bewilderment (0-28), and total mood disturbance (0-200) wherein higher scores indicate greater mood state.

  28. Difference in changes in feeling

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by Feeling Scale; a one-item inventory measuring the extent to which participants feel pleasant or unpleasant. Higher scores indicate more unpleasant feeling. Scored from -5 (very bad) to 5 (very good)

  29. Difference in changes arousal

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by Felt Arousal Scale; a one-item inventory measuring the extent to which participants feel aroused. Higher scores indicate greater arousal (low=1 to high =6).

  30. Difference in willingness to take risks

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by Evaluation of Risks Questionnaire; a 24-item questionnaire providing scores on five scales: self-control, danger seeking, energy, impulsivity, and invincibility.

  31. Difference in risk taking behavior

    Time frame: Study days 7, 20, 21, 41, 42, 62, 63

    Measured by Balloon Analogue Risk Task

  32. Difference in resting metabolic rate

    Time frame: Study days 7, 21, 42, 63

    Resting metabolic rate measured by indirect calorimetry

  33. Difference in physical activity energy expenditure

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Energy expenditure measured by indirect calorimetry during 60-minute steady state exercise

  34. Difference in gastrointestinal transit time

    Time frame: Study days 20, 41, 62

    Gastric, small intestine and large intestine transit time measured by SmartPill

  35. Difference in gastrointestinal pH

    Time frame: Study days 20, 41, 62

    Gastric, small intestine and large intestine pH measured by SmartPill

  36. Difference in changes in working memory

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by N-Back task before, during and after exercise

  37. Difference in changes in spatial working memory

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by emotional Interference task before, during and after exercise

  38. Difference in changes in spatial memory

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by Matching to Sample test in the morning and afternoon

  39. Difference in change in reaction time

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by reaction time task before, during and after exercise

  40. Difference in change in response inhibition

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Measured by Go/No-Go task before, during and after exercise

  41. Difference in vigilance

    Time frame: Study days 20, 21, 23, 41, 42, 44, 62, 63, 65

    Measured by scanning visual vigilance task

  42. Difference in simple visual reaction time

    Time frame: Study days 20, 21, 23, 41, 42, 44, 62, 63, 65

    Measured by psychomotor vigilance test

  43. Difference in language-based logical reasoning

    Time frame: Study days 20, 21, 23, 41, 42, 44, 62, 63, 65

    Measured by grammatical Reasoning task

  44. Difference in ambulatory vigilance

    Time frame: 48-hours/day during study weeks 0, 2, 3, 5, 6, 8, 9

    Measured by wrist-worn vigilance monitor

  45. Difference in fecal short chain fatty acids

    Time frame: Study days 6, 18, 21, 23, 27, 39, 42, 44, 48, 60, 63, 65

    Fecal short chain fatty acid concentrations

  46. Difference in gut microbiota composition

    Time frame: Study days 6, 18, 21, 23, 27, 39, 42, 44, 48, 60, 63, 65

    Fecal bacterial community diversity and relative abundance measured by 16S rRNA gene sequencing

  47. Differences in microRNA concentrations

    Time frame: Study days 20, 21, 41, 42, 62, 63

    Fasting and post-exercise circulating and exosomal microRNA

Sponsors and collaborators

Lead sponsor

United States Army Research Institute of Environmental Medicine

Fed

Collaborators

  • US Army Combat Capabilities Development Command- Soldier Center
  • University of Reading
  • Walter Reed Army Institute of Research (WRAIR)

Registry information

Official study title

Efficacy of a Gut-microbiota Targeted Nutritional Intervention for Promoting Gut Barrier Integrity During Short-term Exposure to Hypobaric Hypoxia.

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Oct 1, 2019
Registry last updated
Dec 23, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.